News

Langhua Pharmaceutical Achieves Milestone with FDA Inspection Success

Langhua Pharmaceutical Achieves Milestone with FDA Inspection Success

Langhua Pharmaceutical's Success in FDA Inspection

Zhejiang Langhua Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Viva Biotech Holdings, recently demonstrated its commitment to quality by successfully passing a cGMP inspection by the U.S. Food and Drug Administration (FDA). This marked the fourth time that Langhua Pharmaceutical has achieved this important milestone, further verifying the effectiveness of its quality control system.

Implications of the FDA Approval

Receiving the Establishment Inspection Report (EIR) from the FDA is significant for Langhua Pharmaceutical. The accomplishment allows the company to provide tailored research, development, and production services globally. It ensures that their facilities meet stringent FDA guidelines, and this success is a testament to their robust operational capabilities.

Broadening Service Horizons

Langhua Pharmaceutical's successful audit comes on the heels of an inspection that evaluated six critical systems including quality assurance, materials handling, production processes, packaging, labeling, equipment, and laboratory control. This comprehensive approach is designed to maintain a high standard of excellence, which is pivotal in the pharmaceutical industry.

Innovative Solutions at Langhua

As a one-stop CDMO (Contract Development and Manufacturing Organization) solution provider, Langhua Pharmaceutical specializes in the lifecycle of small molecule drugs. Their services extend from Active Pharmaceutical Ingredients (APIs) to the Finished Dosage Form (FDF), ensuring efficient, flexible, and quality-driven CDMO services are offered to pharmaceutical enterprises across the globe.

Located in multiple strategic centers, Langhua boasts over 13,000 square meters of lab space and a dedicated team of more than 700 researchers committed to advancing R&D activities. The company has successfully passed various audits and has certification from major global health authorities, thereby enhancing its credibility and capability in the market.

Long-Standing Industry Contributions

Langhua Pharmaceutical has a rich history of contributing to the launch of more than 20 new drugs in diverse therapeutic areas including oncology, diabetes, cardiovascular conditions, and HIV treatment. Their comprehensive product line showcases their commitment to creating effective healthcare solutions.

Leadership Insights

Dr. Cheney Mao, the Chairman and CEO of Viva Biotech, emphasized the significance of passing the FDA inspection. He noted that this achievement is foundational for the company’s ongoing expansion into international markets. The focus moving forward includes enhancing CDMO production capacities and integrating CRO (Contract Research Organization) and CDMO functionalities to better support global partners in drug development.

Mr. Weidong Zhang, Senior Vice President of Viva Biotech and Executive Vice President of Langhua Pharmaceutical, also shared his pride in this recognition from the FDA. He highlighted that maintaining GMP compliance is essential, and the company will persist in strengthening its quality management practices to strive for excellence in CDMO services.

About Viva Biotech

Viva Biotech, established in 2008, specializes in providing integrated services, from early-stage Structure-Based Drug R&D to commercial manufacturing. The company is dedicated to supporting global biopharmaceutical innovators, leveraging cutting-edge technology and expert knowledge. Their team excels in drug discovery and development, addressing a broad spectrum of therapeutic needs.

About Langhua Pharmaceutical

As a vital part of Viva Biotech Holdings, Zhejiang Langhua Pharmaceutical Co., Ltd. engages in extensive research and development, coupled with production, marketing, and sourcing of pharmaceutical products. It prides itself on delivering comprehensive solutions for small molecule drugs, offering partners a seamless experience throughout the drug development lifecycle.

Frequently Asked Questions

What recent achievement did Langhua Pharmaceutical attain?

Langhua Pharmaceutical successfully passed an on-site inspection by the FDA, reinforcing its quality management practices.

How many times has Langhua Pharmaceutical passed FDA inspections?

This is the fourth time Langhua Pharmaceutical has successfully passed an FDA inspection.

What services does Langhua Pharmaceutical provide?

Langhua Pharmaceutical offers CDMO services, covering operations from APIs to ready-to-use drug forms, ensuring quality throughout the drug lifecycle.

What is the role of Viva Biotech in this development?

Viva Biotech oversees the operations of Langhua Pharmaceutical, supporting it in achieving international standards for drug manufacturing.

What future initiatives are planned for Langhua Pharmaceutical?

Langhua intends to enhance its CDMO capacities and integrate its CRO services to better assist global pharmaceutical partners.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 75

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 131

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 30

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 137

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading
Mindstream’s Jordan AI Campus Faces Its First Real Test

Updated Category News Views 39

Jordan’s AI ambitions just got attached to a very large gas meter. Mindstream Energy has unveiled a plan for an AI-ready data-center campus at Al-Risha in Mafraq Governorate, built around dedicated natural-gas generation rather than a conventional dependence on the utility grid. The headline number is 400 megawatts of eventual capacity. The number that matters first is...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Yangtze Documentary Frames a Decade of Economic Change

Updated Category News Views 13

A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 32

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Full Truck Alliance Profits Surge as Revenue Slows

Updated Category News Views 122

A freight platform just delivered the kind of earnings math that makes investors sit up: sales barely jogged, while profit took off running. Full Truck Alliance’s third-quarter report is plainly strong on the surface, with net income up 49.0% year over year to RMB1.37 billion. Still, this is not a clean, uncomplicated growth story. The quality of the margin jump...

Continue Reading

Top 5 Most Recently Viewed Articles

OpenBench and ORIC Pharmaceuticals Forge a ground-breaking alliance

Updated Category News Views 102

OpenBench and ORIC Pharmaceuticals Team Up OpenBench, Inc., known for its innovative AI-driven discovery partnerships in the realm of small molecules, has announced a promising new collaboration with ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC). This partnership aims to utilize OpenBench's advanced success-driven discovery methods alongside its cutting-edge structure-based...

Continue Reading
IMUNON's Q3 2025 Update: Progress and Future Endeavors

Updated Category News Views 135

IMUNON Conference Call Announcement LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN), a pioneering clinical-stage biotechnology firm focusing on breakthrough DNA-mediated immunotherapy, is set to host a conference call at 11:00 a.m. ET on Thursday, November 13, 2025. This call will delve into the company’s financial results for the third quarter ending September 30,...

Continue Reading
Enhancements in Compliance Solutions Transforming MSP Landscape

Updated Category News Views 730

Exciting Upgrades to the Cyber Verify Compliance Platform Cyber Verify, a platform operated by MSPAlliance, has recently undergone significant enhancements aimed at revolutionizing the way Managed Service Providers (MSPs) approach compliance. With these new features, Cyber Verify is not just a tool, but a key partner for MSPs striving to achieve excellence in operational...

Continue Reading
Celebrating Latino Heritage: James Scott Farrin's Impact in 2024

Updated Category News Views 173

Supporting Latino and Hispanic Communities The Law Offices of James Scott Farrin has made remarkable strides in their commitment to supporting Latino and Hispanic communities. This year marks over a decade of their devoted involvement in various initiatives designed to uplift these communities and enhance their rights and opportunities. Sponsorship Highlights for 2024...

Continue Reading
AMTD's Dr. Calvin Choi Solidifies Leadership in HK

Updated Category News Views 20

Dr. Calvin Choi's Reappointment: A Strategic Move Out in the world of high stakes and corporate chess, Dr. Calvin Choi is making moves that echo far beyond the boardrooms. This guy isn't just resting on his laurels; his reappointment as President of the Hong Kong Island Federation spells serious business for AMTD IDEA (NYSE: AMTD), AMTD Digital (NYSE: HKD), and by...

Continue Reading